Moexipril

This classification denotes an ace inhibitor with the molecular formula C27H34N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WT87C52TJZ, chemically known as (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester but generally known as moexipril, which bears US NIH Compound Identifier 91270. European Medicines Agency schedules Moexipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09030MIG. The term MOEXIPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules moexipril in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule moexipril under HS 29334990 and SITC 51575. As of Q4 2014, MOEXIPRIL remains the US FDA Preferred Term for this commodity. Moexipril bears US NLM identifiers UMLS ID C0066685 and NCI Concept Code C83967. SMILES: O=C(N1C(Cc2c(C1)cc(OC)c(OC)c2)C(=O)O)C(NC(CCc1ccccc1)C(=O)OCC)C.